Rucaparib

View All

Prostate Cancer Market
Prostate Cancer Market Experiences an Influx of the Pharma Players Veering the Market Ahead

Prostate Cancer Market Size is Expected to Increase with a CAGR of 8.1% in the 7MM for the study period of 2017-30 owing to rich Pipeline, Increasing Awareness and Better Treatment Options. A malignancy of prostate glands, Prostate Cancer, develops slowly and remains confined to prostate glands, however, can inv...

Find More

Opdivo for carcinoma; Rucaparib receives designation; Sunovion buys; Insys marketed drug

Game changing agent, Opdivo, on a threshold to change standard of care in squamous cell carcinoma of the head and neck (SCCHN) According to Dr. Robert Ferris, who is vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of ...

Find More